Fibroblast Activation Protein Inhibitor Theranostics

Area of Science:

• Oncology
• Radiochemistry
• Molecular Imaging

Background:

• Fibroblast activation protein (FAP) is a key biomarker in various cancers.
• Current PET imaging relies heavily on [fluorine-18] fluoro-2-deoxy-d-glucose (18F-FDG).
• There is a need for complementary imaging agents to provide more specific phenotypic information.

Purpose of the Study:

• To highlight the evolution and potential of fibroblast activation protein inhibitor (FAPI) molecules as theranostic agents.
• To explore the complementary role of FAPI tracers alongside 18F-FDG in PET/CT.
• To discuss the application of FAPI in directing fibroblast activation protein-targeted therapies.

Main Methods:

• Review of the development of FAPI molecules over the past decade.
• Comparison of FAPI tracers with 18F-FDG in terms of diagnostic and therapeutic potential.
• Discussion of FAPI's role in personalized medicine and targeted therapy.

Main Results:

• FAPI inhibitors have advanced significantly, offering theranostic capabilities.
• FAPI tracers demonstrate potential to match or complement 18F-FDG in PET/CT imaging.
• These agents can provide valuable phenotypic and biomarker insights.

Conclusions:

• FAPI inhibitors represent a promising new class of theranostic agents in oncology.
• FAPI tracers are expected to become complementary to 18F-FDG, enhancing diagnostic accuracy.
• Future applications include guiding FAP-targeted therapies for improved patient outcomes.